Vaccitech prices shares at $17 for U.S. IPO

Barinthus Biotherapeutics

30/04/2021 01:15

April 29 (Reuters) - Vaccitech Plc  VACC.O , the biotech
startup that owns the technology behind the COVID-19 vaccine
developed by Oxford University and AstraZeneca Plc  AZN.L ,
priced its ordinary shares at $17 each on Thursday ahead of its
U.S. initial public offering.
    The British company expects gross proceeds of $110.5 million
from the offering of 6.5 mln of its American Depositary Shares
(ADSs), representing the same number of ordinary shares. (https://refini.tv/3e2Jhct)
    Vaccitech had announced its plans to go public earlier this
month and said the ADSs would begin trading on the Nasdaq under
the symbol "VACC" on April 30.  urn:newsml:reuters.com:*:nL4N2M23WN
    Its preference for a U.S. listing to one in the UK could
further undermine London's attempts to become a major financial
hub, particularly after Brexit.
    The company expects the offering to close on May 4.
    Morgan Stanley, Jefferies, Barclays and William Blair are
acting as bookrunners for the offering. H.C. Wainwright & Co is
acting as the lead manager for the offering.

 (Reporting by Trisha Roy in Bengaluru; Editing by Subhranshu
Sahu)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))